UPDATE : Monday, December 16, 2019
상단여백
Voluntary nullifications of drug license tripled in H1
An increasing number of pharmaceutical companies voluntarily canceled the l...
by Lee Hye-seon  |  2019-06-26 14:25
라인
Seoul Pharma to export erectile dysfunction treatment to Azerbaijan
Seoul Pharmaceuticals has signed an agreement with Loghman Pharmaceutical o...
by Lee Han-soo  |  2019-06-26 13:58
라인
Novartis’ Tasigna confirms long-term success for chronic myelogenous leukemia
Novartis has reaffirmed the long-term success of Tasigna (Ingredient: Nilot...
by Lee Han-soo  |  2019-06-26 11:39
라인
Huons Global launches new BTX in Korea
Huons Global plans to launch a new botulinum toxin (BTX) product in Korea. ...
by Lee Han-soo  |  2019-06-26 10:52
라인
Hanmi, Sanofi revise accord on co-developing diabetes drug
Hanmi Pharmaceutical said it has signed a revised agreement with Sanofi to ...
by Lee Han-soo  |  2019-06-25 17:36
라인
‘Imbruvica raised survival rate of mantle cell lymphoma patients’
“Imbruvica works better than any other existing chemotherapy in relapsed an...
by Kim Yun-mi  |  2019-06-25 15:34
라인
CHA Biotech to transfer SCRMI’s shares, technology to AIRM
CHA Biotech said that it would transfer shares and technologies of Stem Cel...
by Lee Han-soo  |  2019-06-25 15:25
라인
Regulator OKs P3 trial for Eisai's Alzheimer treatment
The Ministry of Food and Drug Safety has approved the phase 3 clinical tria...
by Lee Han-soo  |  2019-06-25 14:09
라인
Novartis’ Cosentyx shows durable, comprehensive treatment for psoriatic disease
Novartis has released new data on five-year long-term immunogenicity and in...
by Lee Han-soo  |  2019-06-25 14:09
라인
Celltrion denies delay in local license application for HIV drug Temixys
The Ministry of Food and Drug Safety and Celltrion said rumors about the dr...
by Lee Hye-seon  |  2019-06-25 10:56
라인
Latecomer experimental drug no better than Dupixent in trial
Pharmaceutical firms have strived to make latecomer drugs to beat Dupixent ...
by Kim Yun-mi  |  2019-06-24 15:49
라인
Daewoong wins new indications for Nabota
Daewoong Pharmaceutical's Nabota, its botulinum toxin (BTX) strain, has...
by Lee Han-soo  |  2019-06-24 14:47
라인
Kang Stem Biotech completes P3 trials for stem cell-based atopy treatment
Kang Stem Biotech has completed the subject evaluation of phase 3 clinical ...
by Lee Han-soo  |  2019-06-24 12:19
라인
Anti-cancer Sutene could cause central nervous system abnormality in fetus
Pfizer Korea’s renal cancer treatments Sutene Cap. (ingredient: sunitinib m...
by Lee Hye-seon  |  2019-06-24 11:35
라인
Boryung calls off ₩83-billion supply contract in Jordan
Boryung Pharmaceutical said that it has canceled its contract to supply 83 ...
by Lee Han-soo  |  2019-06-21 18:00
라인
MSD’s antibiotic Zerbaxa fails to get insurance coverage
MSD Korea’s antibiotic drug Zerbaxa Inj. failed to receive insurance covera...
by Kim Eun-young  |  2019-06-21 14:13
라인
‘Customized strategies needed for fast-changing Chinese drug regulation’
Foreign drugmakers need to make the most of China’s revised drug regulation...
by Jeong Sae-im  |  2019-06-21 14:12
라인
Off-label use of Mabthera Inj. denied
The Health Insurance Review and Assessment Service (HIRA) said it has disap...
by Kim Yun-mi  |  2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’
The Korean Cancer Study Group (KCSG) said Korean institutions and researche...
by Kim Yun-mi  |  2019-06-20 15:04
라인
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis
AbbVie has recently announced the latest results from the phase 3 clinical ...
by Lee Han-soo  |  2019-06-19 16:27
여백
여백
여백
Back to Top